Natural killer cell therapy and aerosol interleukin‐2 for the treatment of osteosarcoma lung metastasis. Issue 4 (18th October 2013) - Guma, Sergei R.
Abstract Background Survival of patients with osteosarcoma lung metastases has not improved in 20 years. We evaluated the efficacy of combining natural killer (NK) cells with aerosol interleukin‐2 (IL‐2) to achieve organ‐specific NK cell migration and expansion in the metastatic organ, and to decrease toxicity associated with systemic IL‐2. Procedure Five human osteosarcoma cell lines and 103 patient samples (47 primary and 56 metastatic) were analyzed for NKG2D ligand (NKG2DL) expression. Therapeutic efficacy of aerosol IL‐2 + NK cells was evaluated in vivo compared with aerosol IL‐2 alone and NK cells without aerosol IL‐2. Results Osteosarcoma cell lines and patient samples expressed various levels of NKG2DL. NK‐mediated killing was NKG2DL‐dependent and correlated with expression levels. Aerosol IL‐2 increased NK cell numbers in the lung and within metastatic nodules but not in other organs. Therapeutic efficacy, as judged by tumor number, size, and quantification of apoptosis, was also increased compared with NK cells or aerosol IL‐2 alone. There were no IL‐2‐associated systemic toxicities. Conclusion Aerosol IL‐2 augmented the efficacy of NK cell therapy against osteosarcoma lung metastasis, without inducing systemic toxicity. Our data suggest that lung‐targeted IL‐2 delivery circumvents toxicities induced by systemic administration. Combining aerosol IL‐2 with NK cell infusions, may be a potential new therapeutic approach for patients with osteosarcoma lung metastasis. Pediatr Blood Cancer 2014;61:618–626. © 2013 Wiley Periodicals, Inc.